Testing effectiveness (Phase 2)Study completedNCT00431015
What this trial is testing
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Who this might be right for
Lung Cancer
Infinity Pharmaceuticals, Inc. 88